Hemodynamic Support in Ventricular Tachycardia Ablation: An International VT Ablation Center Collaborative Group Study

Mohit K. Turagam, Venkat Vuddanda, Donita Atkins, Pasquale Santangeli, David S. Frankel, Roderick Tung, Marmar Vaseghi, William H. Sauer, Wendy Tzou, Nilesh Mathuria, Shiro Nakahara, Timm M. Dickfeld, T. Jared Bunch, Peter Weiss, Luigi Di Biase, Venkat Tholakanahalli, Kairav Vakil, Usha B. Tedrow, William G. Stevenson, Paolo Della BellaKalyanam Shivkumar, Francis E. Marchlinski, David J. Callans, Andrea Natale, Madhu Reddy, Dhanunjaya Lakkireddy

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Objectives This study sought to evaluate the clinical outcomes of patients receiving hemodynamic support (HS) during ventricular tacchycardia (VT) ablation. Background There are limited real-world data evaluating its effect of HS in ablation outcomes. Methods An analysis of 1,655 patients from the International VT Ablation Center Collaborative group was performed. A total of 105 patients received HS with percutaneous ventricular assist device. Results Patients in the HS group had lower left ventricular ejection fraction (LVEF), higher New York Heart Association (NYHA) functional class, and more implantable cardioverter-defibrillator (ICD) shocks, VT storm, and antiarrhythmic drug use (all p < 0.05). The HS group also required significantly longer fluoroscopy, procedure, and total lesion time. Acute procedural success (71.8% vs. 73.7%; p = 0.04) was significantly lower and complications (12.5% vs. 6.5%; p = 0.03) and 1-year mortality (34.7% vs. 9.3%; p < 0.001) were significantly higher in the HS group. Multivariate Cox regression analysis demonstrated HS as an independent predictor of mortality (hazard ratio: 5.01; 95% confidence interval: 3.44 to 7.20; p < 0.001). There was no significant difference in VT recurrence between groups. In a subgroup analysis including LVEF ≤20% and NYHA functional class III to IV patients, acute procedural success (74.0% vs. 70.5%; p = 0.8), complications (15.6% vs. 7.8%; p = 0.2), VT recurrence (30.2% vs. 38.1%; p = 0.44), and 1-year mortality (40.0% vs. 28.8%; p = 0.2) were no different between the HS and no-HS groups. Conclusions Patients requiring HS were sicker with multiple comorbidities and, as expected, had a significantly higher 1-year mortality than did those patients in the no-HS group. In patients with LVEF ≤20% and NYHA functional class III to IV, there was also no significant difference in clinical outcomes when compared with no HS. Further studies are needed to systematically evaluate patients undergoing VT ablation receiving HS.

Original languageEnglish (US)
Pages (from-to)1534-1543
Number of pages10
JournalJACC: Clinical Electrophysiology
Issue number13
StatePublished - Dec 26 2017
Externally publishedYes


  • catheter ablation
  • hemodynamic support
  • percutaneous ventricular assist device
  • ventricular tachycardia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Hemodynamic Support in Ventricular Tachycardia Ablation: An International VT Ablation Center Collaborative Group Study'. Together they form a unique fingerprint.

Cite this